Recent Progresses in Non-Dialysis Chronic Kidney Disease Patients with Hyperkalemia: Outcomes and Therapeutic Strategies

• Published in: Medicina (Kaunas, Lithuania) Vol. 59; no. 2; p. 353
• Main Authors: Tian, Ruixue, Li, Rongshan, Zhou, Xiaoshuang
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 01.02.2023; MDPI
• Subjects: Cardiovascular disease; chronic kidney disease; Chronic kidney failure; Clinical medicine; Complications and side effects; Diabetes; Diuretics; Drug therapy; Electrocardiography; Food; Heart failure; Hemodialysis; Homeostasis; Humans; Hyperkalemia; Hypokalemia; Kidney; Kidney diseases; Mortality; Nonsteroidal anti-inflammatory drugs; Patient outcomes; Peritoneal dialysis; Polymers - therapeutic use; Potassium; Renal Insufficiency, Chronic - complications; Review; Risk factors; China; chronic kidney disease; potassium; hyperkalemia
• ISSN: 1648-9144; 1010-660X; 1648-9144
• DOI: 10.3390/medicina59020353

Chronic kidney disease (CKD) affects about 10% of the world's population. Hyperkalemia is a life-threatening complication in patients with CKD, as it is associated with adverse cardiovascular and kidney outcomes. There are still many challenges and questions to address to improve the currently available therapeutic strategies to treat hyperkalemia, such as how to approach the emergency management of hyperkalemia. In recent years, in addition to novel oral potassium binders, great progress has been made in the application of novel kidney protective strategies, such as mineralocorticoid receptor antagonists and sodium-glucose cotransporter 2 inhibitors (SGLT2i) in hyperkalemia therapy. This review will discuss the recent advances from clinical trials in the effective management of hyperkalemia in non-dialysis CKD patients, enhancing the knowledge of physicians and internists concerning these newer agents and providing a helpful reference for clinical practice.